ArticleInternational journal of clinical and experimental pathology2021
NPC2 expression in thyroid tumors and its possible diagnostic utility.
Article in International journal of clinical and experimental pathology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 6 citations in OpenAlex.
- Analysis and validation of prognostic markers for thyroid cancer by single-cell and bulk RNA sequencing.Translational cancer research · 2026Article
- Comprehensive Multi-Omics Analysis Reveals NPC2 and ITGAV Genes as Potential Prognostic Biomarkers in Gastrointestinal Cancers.Cancer reports (Hoboken, N.J.) · 2024Article
- The role of NPC2 gene in glioma was investigated based on bioinformatics analysis.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Histopathologic diagnosis of thyroid lesions is sometimes difficult and may require the assistance of immunohistochemistry. Currently-used immunohistochemical biomarkers share the weakness of staining both papillary thyroid carcinoma and other non-papillary thyroid lesions. We examined NPC2 as an immunohistochemical marker in various thyroid lesions to determine the subcellular localization of the immunohistochemistry signal and evaluated the value of NPC2 as a diagnostic marker of papillary thyroid carcinoma. NPC2 immunostaining was performed on various thyroid tumors and tumor-like lesions. The immunostaining revealed significantly different patterns for papillary carcinomas and the other lesions. Papillary carcinomas exhibited moderate to strong granular cytoplasmic staining, often with basal membranous accentuation. In contrast, the other lesions showed mostly weak cytoplasmic staining, often with apical membranous accentuation. The subcellular localization of NPC2 provided insight into contrasting histopathologic morphology and reversed cellular polarity between the papillary patterns of papillary carcinomas and the follicular patterns of non-papillary carcinoma lesions. The diagnostic characteristics of NPC2 immunohistochemistry for non-follicular papillary carcinomas versus non-papillary carcinoma lesions were a sensitivity of 97.3%, specificity of 96.9%, positive predictive value of 94.7%, and negative predictive value of 98.4%. Significant differences were present between the two staining patterns in papillary carcinoma relative to mean age, nodal metastasis, and follicular and non-follicular variants (
Indexed as
Identifiers
33532030PMC7847500W3128284137What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.